{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:28:30Z","timestamp":1793662110536,"version":"4.5.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Omadacycline is an aminomethylcycline antibiotic in the tetracycline class that was approved by the US FDA in 2018 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It is available in both IV and oral formulations. Omadacycline has broad-spectrum in vitro activity and clinical efficacy against infections caused by Gram-positive and Gram-negative pathogens. Omadacycline is being evaluated in a 3\u2005month placebo-controlled Phase 2 clinical trial of oral omadacycline versus placebo in adults with non-tuberculous mycobacteria (NTM) pulmonary disease caused by Mycobacterium abscessus (NCT04922554).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine if omadacycline has intracellular antimicrobial activity against NTM, bacteria that can cause chronic lung disease, in an ex vivo model of intracellular infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Two strains of M. abscessus were used to infect THP-1 macrophages. Intracellular M. abscessus was then challenged with omadacycline and control antibiotics at multiples of the MIC over time to evaluate intracellular killing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At 16\u200a\u00d7\u200a the MIC at 72\u2005h, omadacycline treatment of intracellular NTM yielded a log10 reduction in cfu of 1.1 (91.74% reduction in cfu) and 1.6 (97.65% reduction in cfu) consistent with killing observed with tigecycline, whereas amikacin and clarithromycin at 16\u200a\u00d7\u200a the MIC did not show any reduction in cfu against the intracellular M. abscessus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Omadacycline displayed intracellular activity against M. abscessus within macrophages. The activity was similar to that of tigecycline; as expected, intracellular killing was not observed with clarithromycin and amikacin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlad104","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T13:48:13Z","timestamp":1694785693000},"source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of omadacycline against intracellular <i>Mycobacterium abscessus<\/i> in an infection model in human macrophages"],"prefix":"10.1093","volume":"5","author":[{"given":"S","family":"Jahanbakhsh","sequence":"first","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center , Kalamazoo, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Howland","sequence":"additional","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center , Kalamazoo, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M O","family":"Ndayishimiye Uwineza","sequence":"additional","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center , Kalamazoo, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M T","family":"Thwaites","sequence":"additional","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center , Kalamazoo, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Pillar","sequence":"additional","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center , Kalamazoo, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A W","family":"Serio","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc. , King of Prussia, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D M","family":"Anastasiou","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc. , King of Prussia, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D A","family":"Hufnagel","sequence":"additional","affiliation":[{"name":"Microbiologics Antibiotic and Microbiome Research Center , Kalamazoo, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"2023091509154276600_dlad104-B1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0033-1333573","article-title":"Underlying host risk factors for nontuberculous mycobacterial lung disease","volume":"34","author":"Chan","year":"2013","journal-title":"Semin Respir Crit Care Med"},{"key":"2023091509154276600_dlad104-B2","doi-asserted-by":"crossref","first-page":"e0081220","DOI":"10.1128\/IAI.00812-20","article-title":"Nontuberculous mycobacteria, macrophages, and host innate immune response","volume":"89","author":"Shamaei","year":"2021","journal-title":"Infect Immun"},{"key":"2023091509154276600_dlad104-B3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1086\/323126","article-title":"Nosocomial infections due to nontuberculous mycobacteria","volume":"33","author":"Phillips","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2023091509154276600_dlad104-B4","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3201\/2109.141634","article-title":"Mycobacterium abscessus complex infections in humans","volume":"21","author":"Lee","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2023091509154276600_dlad104-B5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/microorganisms7030090","article-title":"Mycobacterium abscessus: environmental bacterium turned clinical nightmare","volume":"7","author":"Lopeman","year":"2019","journal-title":"Microorganisms"},{"key":"2023091509154276600_dlad104-B6","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(13)60632-7","article-title":"Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study","volume":"381","author":"Bryant","year":"2013","journal-title":"Lancet"},{"key":"2023091509154276600_dlad104-B7","author":"FDA","year":"2018"},{"key":"2023091509154276600_dlad104-B8","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/cid\/ciz395","article-title":"Microbiology and preclinical review of omadacycline","volume":"69","author":"Karlowsky","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023091509154276600_dlad104-B9","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2023091509154276600_dlad104-B10","doi-asserted-by":"crossref","first-page":"e01947-20","DOI":"10.1128\/AAC.01947-20","article-title":"In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023091509154276600_dlad104-B11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mimet.2018.03.020","article-title":"Evaluation of the intracellular activity of drugs against Mycobacterium abscessus using a THP-1 macrophage model","volume":"148","author":"Molina-Torres","year":"2018","journal-title":"J Microbiol Methods"},{"key":"2023091509154276600_dlad104-B12","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Thirty-Second Edition: M100","author":"CLSI","year":"2022"},{"key":"2023091509154276600_dlad104-B13","volume-title":"Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes\u2014First Edition: M62","author":"CLSI","year":"2018"},{"key":"2023091509154276600_dlad104-B14","volume-title":"Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes\u2014Third Edition: M24","author":"CLSI","year":"2018"},{"key":"2023091509154276600_dlad104-B15","doi-asserted-by":"crossref","first-page":"e1002628","DOI":"10.1371\/journal.ppat.1002628","article-title":"Membrane damage during Listeria monocytogenes infection triggers a caspase-7 dependent cytoprotective response","volume":"8","author":"Cassidy","year":"2012","journal-title":"PLoS Pathog"},{"key":"2023091509154276600_dlad104-B16","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1089\/mdr.2017.0286","article-title":"Activities of dual combinations of antibiotics against multidrug-resistant nontuberculous mycobacteria recovered from patients with cystic fibrosis","volume":"24","author":"Schwartz","year":"2018","journal-title":"Microb Drug Resist"},{"key":"2023091509154276600_dlad104-B17","doi-asserted-by":"crossref","first-page":"e0170421","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023091509154276600_dlad104-B18","doi-asserted-by":"crossref","first-page":"e01135-17","DOI":"10.1128\/AAC.01135-17","article-title":"Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects","volume":"61","author":"Gotfried","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023091509154276600_dlad104-B19","doi-asserted-by":"crossref","first-page":"2000535","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"2023091509154276600_dlad104-B20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease","volume":"161","author":"Griffith","year":"2022","journal-title":"Chest"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/5\/dlad104\/51565349\/dlad104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/5\/dlad104\/51565349\/dlad104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T13:48:29Z","timestamp":1694785709000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlad104\/7274348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlad104","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,9,4]]},"article-number":"dlad104"}}